Overview

Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine

Status:
Unknown status
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this migraine prevention study is to evaluate the efficacy and safety of AST-726 in moderate to severe migraine patients at one of two doses compared to placebo and compared to a baseline period as measured by a reduction in the number of migraine days.
Phase:
Phase 2
Details
Lead Sponsor:
Ariston Pharmaceuticals, Inc.